Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update

• Published in: Current pharmaceutical design Vol. 25; no. 3; p. 343
• Main Authors: Guo, Hong-Li, Jing, Xia, Sun, Jie-Yu, Hu, Ya-Hui, Xu, Ze-Jun, Ni, Ming-Ming, Chen, Feng, Lu, Xiao-Peng, Qiu, Jin-Chun, Wang, Tengfei
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2019
• Subjects: Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Antioxidants - therapeutic use; Carnitine - therapeutic use; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; Liver - drug effects; Liver - pathology; Valproic Acid - adverse effects; Valproic Acid - therapeutic use; genetic variants; liver injury; management; glucuronic acid conjugation; β-oxidation; antiepileptic treatment; Valproic acid; oxidative stress

Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity. Long-term VPA therapy is also related to increased risk for the development of non-alcoholic fatty liver disease (NAFLD). In this review, metabolic elimi...